Lensar Inc.’s cornea-cutting laser has received 510(k) FDA clearance for cataract surgery, the company announced Thursday. The Lensar Laser System is cleared to perform corneal and arcuate incisions, which are done on the periphery of the cornea during surgery, as well as lens fragmentation and anterior capsulotomy (with or without phacofragmentation) during cataract surgery. “Until recently, these small and challenging incisions in the cornea were made manually, leading to variability in predictable outcomes,” said Dr. Louis “Skip” Nichamin, a member of Lensar’s medical advisory board. “Lensar’s advanced technology platform will help cataract surgeons achieve consistent, predictable arcuate incision outcomes, regardless of the challenges and complexity of the procedure.” The device provides physicians with an advanced platform for conducting bladeless cataract surgery and achieving consistent, predictable outcomes. The platform features next-generation differentiating Augmented Reality technology consisting of proprietary high-resolution imaging and measurement technology that provides precise biometric information and 3-D reconstruction of the anterior anatomy of the eye. The system, which easily adapts to existing surgical facilities, is available in the US, Europe and several other countries. For more information, visit: www.lensar.com